An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer
Nature Medicine2017Vol. 23(8), pp. 929–937
Citations Over TimeTop 10% of 2017 papers
Jenny Y. Xue, Luciano G. Martelotto, Timour Baslan, Alberto Vides, Martha Solomon, Trang Thi, Neelam Chaudhary, Greg J. Riely, Bob T. Li, Kerry Scott, Fabiola Cechhi, Ulrika Stierner, Kalyani Chadalavada, Elisa de Stanchina, Sarit Schwartz, Todd Hembrough, Gouri J. Nanjangud, Michael F. Berger, Jonas A. Nilsson, Scott W. Lowe, Jorge S. Reis‐Filho, Neal Rosen, Piro Lito
Related Papers
- → Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma(2014)121 cited
- → The crossregulation between ERK and PI3K signaling pathways determines the tumoricidal efficacy of MEK inhibitor(2012)71 cited
- → Resistance to Mitogen-Activated Protein Kinase Kinase (MEK) Inhibitors Correlates with Up-Regulation of the MEK/Extracellular Signal-Regulated Kinase Pathway in Hepatocellular Carcinoma Cells(2009)34 cited
- → Abstract 2150: Alternative treatment strategies to overcome MAPK inhibitor resistance in melanoma(2016)
- → A functional measurement of MAPK pathway activation to predict response to MEK inhibitors in RAS-mutated patients.(2019)